SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1610The following publication by Regeneron scientists is a major breakthrough in conBiotech Jim-9/13/2013
1609Lucentis and Eylea will be dosed according to the FDA label. The curious featureDewDiligence_on_SI-9/13/2013
1608Hmmm interesting they are comparing with Eylea considering they have a pdgf-B anFelix B-9/12/2013
1607OPHT’s phase-3 Fovista trials are now on ctg: Lucentis ± Fovista ( cliniDewDiligence_on_SI-9/12/2013
1606Even though they are "neck and neck", REGN will be filing a year earlyFelix B-9/3/2013
1605PharmaTimes on the current state of PCSK9 affairs: pharmatimes.comBiotech Jim-9/2/2013
1604Amgen pooled 12 week data for the PSCK9 sequestering antibody program released aBiotech Jim-9/1/2013
1603Roche phase-2 data in dry AMD: siliconinvestor.comDewDiligence_on_SI-8/27/2013
1602A few years ago, Genentech partnered with SRDX to develop a slow-release formulaDewDiligence_on_SI-8/19/2013
1601Is this competition for Eylea? or is it REGN's technology? Public ReleaseIan@SI-8/19/2013
1600REGN reports earnings this morning, August 6, 2013. Regeneron Reports Second QBiotech Jim-8/6/2013
1599Short interest goes up for REGN, could be a driver for higher prices upon the shBiotech Jim-7/25/2013
1598For either the FWIW or WGAS column, I did buy back some of the shares of REGN yeBiotech Jim-6/21/2013
1597Optina in DME? Here is the trial design: "The multicenter trial is designBiotech Jim-5/29/2013
1596Any thoughts on this? seekingalpha.comFelix B-5/28/2013
1595REGN buys back from SNY the rights to 2 ocular programs, PDGF and Ang 2 antibodiBiotech Jim-5/3/2013
1594Jim, the AGN drug that was in the news yesterday, AGN-150998, inhibits VEGF onlyDewDiligence_on_SI15/2/2013
1593Hey Dew, for the Darpin molecule, I saw a Nov 2012 PR from AGN that said that thBiotech Jim-5/2/2013
1592So much fun, going through the early days of this thread. Nobody should pass thscaram(o)uche35/1/2013
1591Musings on AGN’s woes today: siliconinvestor.com Genisi (a/k/a idos on SI) anDewDiligence_on_SI-5/1/2013
1590REGN en fuego!! Edit 3 min later - T7 trading halt. Edit #2 5 min later - resBiotech Jim-5/1/2013
1589REGN to go into the S & P 500. bloomberg.comBiotech Jim-4/24/2013
1588Just a wild guess, as the stock breaks to a new all time high. Time for dupilBiotech Jim-4/4/2013
1587How can you tell? You think this is due to recent price increase?Felix B-4/4/2013
1586Looks like SNY started buying the shares of REGN on the open market!Biotech Jim-3/19/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News